ArticlePloS one2012
RUNX3 regulates intercellular adhesion molecule 3 (ICAM-3) expression during macrophage differentiation and monocyte extravasation.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Solubility based mechanistic profiling of combinatorial drug therapy.Nature communications · 2026Article
- ITGB2 and ICAM3 predict increased survival of sepsis with decreased intercellular communication in cytotoxic CD8+ T cells.Scientific reports · 2025Article
- Intercellular Adhesion Molecule 3: Structure, Cellular Functions, and Emerging Role in Human Diseases.Journal of Cancer · 2025Review
- Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.European journal of haematology · 2025Article
- The ENCODE mouse postnatal developmental time course identifies regulatory programs of cell types and cell states.bioRxiv : the preprint server for biology · 2024Article
- Review
- Investigating the Role of Inflammatory Response in Polycystic Ovary Syndrome Using Integrated RNA-Seq Analysis.Journal of inflammation research · 2024Article
- Transcriptomic Context ofBiomedicines · 2023Article
- RUNX regulated immune-associated genes predicts prognosis in breast cancer.Frontiers in genetics · 2022Article
- Disruption of c-MYC Binding and Chromosomal Looping Involving Genetic Variants Associated With Ankylosing Spondylitis Upstream of theFrontiers in genetics · 2021Article
- Neonatal monocytes demonstrate impaired homeostatic extravasation into a microphysiological human vascular model.Scientific reports · 2020Article
- Regeneration associated transcriptional signature of retinal microglia and macrophages.Scientific reports · 2019Article
- ICAM3 mediates inflammatory signaling to promote cancer cell stemness.Cancer letters · 2018Article
- Evidence for a second ankylosing spondylitis-associatedRMD open · 2018Article
- Runx2 deletion in smooth muscle cells inhibits vascular osteochondrogenesis and calcification but not atherosclerotic lesion formation.Cardiovascular research · 2016Article
- The RUNX complex: reaching beyond haematopoiesis into immunity.Immunology · 2015Review
- MicroRNA expression profiling of human blood monocyte subsets highlights functional differences.Immunology · 2015Article
- Effect and mechanism of RUNX3 gene on biological characteristics of human esophageal squamous cell carcinoma (ESCC).Medical oncology (Northwood, London, England) · 2015Article
- Impact of fibroblast activation protein on osteosarcoma cell linesOncology letters · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adhesion molecule ICAM-3 belongs to the immunoglobulin gene superfamily and functions as a ligand for the β2 integrins LFA-1, Mac-1 and α(d)β(2). The expression of ICAM-3 is restricted to cells of the hematopoietic lineage. We present evidences that the ICAM-3 gene promoter exhibits a leukocyte-specific activity, as its activity is significantly higher in ICAM-3+ hematopoietic cell lines. The activity of the ICAM-3 gene promoter is dependent on the occupancy of RUNX cognate sequences both in vitro and in vivo, and whose integrity is required for RUNX responsiveness and for the cooperative actions of RUNX with transcription factors of the Ets and C/EBP families. Protein analysis revealed that ICAM-3 levels diminish upon monocyte-derived macrophage differentiation, monocyte transendothelial migration and dendritic cell maturation, changes that correlate with an increase in RUNX3. Importantly, disruption of RUNX-binding sites led to enhanced promoter activity, and small interfering RNA-mediated reduction of RUNX3 expression resulted in increased ICAM-3 mRNA levels. Altogether these results indicate that the ICAM-3 gene promoter is negatively regulated by RUNX transcription factors, which contribute to the leukocyte-restricted and the regulated expression of ICAM-3 during monocyte-to-macrophage differentiation and monocyte extravasation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.